Pharmaceutical Wholesale Distributor
The industry — Pharmaceuticals, toiletries, cosmetics and sundries merchant wholesalers
Base industry report for 4145 →- Establishments · CanadaA
- 1,538
- Under 10 employeesA
- 65%
Of 1,538 Canadian establishments with employees, 65% have fewer than ten — mostly small operators.
Entry signal — what decides who wins here
One thing must be trueEntry turns on a single condition that can be named and tested before much is spent. Clear it and this becomes an execution question; fail it and no amount of operating skill helps.
Prove the value in money the buyer already counts. The need is real; what is unproven is that this buyer moves budget for it. That is a priced test with real customers, not a product problem.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 6
The binding constraint — willingness to pay
Demand could not be steadier: distributors carry 91% of Canada's prescription medicines to more than 12,000 dispensing points, most orders inside 24 hours [C]. The cut is what the service is paid. McKesson's North American Pharmaceutical segment — which includes its Canadian distribution business — took $336.7B of revenue in fiscal 2026 and kept $3.5B of adjusted operating profit: a 1.03% margin, identical to the year before [A]. That is the world's largest operator, after decades of automation. In Canada the distributor's fee is not negotiated in a market at all; it is an allowance written into provincial drug-plan pricing, and the distributors' own association says that funding has been roughly flat for more than fifteen years while operating costs rose 23% across 2021–22 [C]. A payer that has held the fee through that has told an entrant what it will pay. On top sit a Health Canada establishment licence, controlled-substance security and cold chain — real costs, but survivable ones. The fee is what is not. The 1,538 establishments are mostly not full-line drug distributors: 636 employ fewer than five people, and many sit on the toiletries and cosmetics side, which this screen did not examine; the 3256 record covers how flat that category is.
Full-line pharmaceutical distribution is a national network of regional warehouses serving chains whose supply contracts are let at head office, under a federal establishment licence and provincially set reimbursement. An entrant cannot win one city: the customer is a chain or a banner, and the price is a provincial schedule.
Who you would be competing with
The operators already at scale here, and whoever is buying these businesses. In most of these industries the competition an entrant meets is local, so this is who sets the terms rather than a list of everyone in the trade.
Financials & market size — sourced
Figures that came from a filing, a results release or reputable reporting, each carrying its evidence tier.
Market size, derived
Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.
Disclosed revenue from 1 of 5 named vendors. The market is at least this large.
No vendor has both a disclosed revenue and a published share.
Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.
Competitor set · 5 named · 1 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| McKesson CanadaNYSE: MCKA | $336.7B | — | North American Pharmaceutical segment revenue, fiscal 2026 — overwhelmingly US, with Canadian distribution inside it and not separately reported |
| Kohl & FrischC | not disclosed | — | The large independent Canadian full-line distributor; privately held and publishes nothing |
| Banner-owned distribution (Shoppers Drug Mart, Jean Coutu, Familiprix)C | not disclosed | — | The largest pharmacy banners supply their own stores, which removes those dispensing points from an independent wholesaler’s addressable market; none reports distribution separately and the ownership of each banner was not re-verified for this record |
| Cencora (Innomar Strategies) and Cardinal Health CanadaC | not disclosed | — | Specialty, biologics and hospital supply rather than full-line retail distribution; neither breaks out Canada, and neither was researched for this record |
| UPS Healthcare / Andlauer Healthcare GroupNYSE: UPSA | not disclosed | — | UPS bought Andlauer for CAD $55.00 a share, about C$2.2B, completing November 2025 — healthcare logistics and cold chain, not full-line wholesaling, and the clearest recent price for an asset adjacent to this industry |
Evidence
Evidence. McKesson's segment revenue, adjusted operating profit and margin were read from the fiscal 2026 results exhibit filed with the SEC [A], as was the fiscal 2025 loss on its Canadian disposal. McKesson's fiscal 2026 10-K states that the segment covers distribution and logistics in the U.S. and Canada, and that the Canadian operations moved into it in the second quarter of fiscal 2026 from the former International segment [A]. That segment is overwhelmingly US revenue with Canada inside it; McKesson does not report Canadian distribution separately, so no Canadian margin is on this record. The CAPDM figures come from the association's July 2025 release about a report it commissioned [C]: it is an interested party arguing for higher fees, and the underlying IQVIA analysis was not opened. The provincial allowance schedules themselves were not read, so the statement that the fee is payer-set rests on general knowledge of Canadian drug pricing, not on a document opened for this screen. Toiletries, cosmetics and sundries wholesaling (414520) was not examined. The cut factor is analyst judgment. The competitive field, added in the completion pass: the Andlauer terms — CAD $55.00 a share, about C$2.2B (US$1.6B), completed November 2025 — are read from UPS’s own press release [A]. Andlauer is named because it prices the adjacent asset, not because it is a competing wholesaler: it is a healthcare third-party logistics and cold-chain business, and that release publishes no revenue, network size or customer count for it. The other names in the block are private, or do not report Canada separately; no figure is claimed for any of them, and the ownership of the pharmacy banners was not re-verified here. No transaction price for a Canadian full-line pharmaceutical wholesaler was found, and the record does not imply one exists.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
Represents Canadian healthcare distributors; Member Forum Sept 2026 and Annual Conference 2026 on site. No member count published.
US primary pharmaceutical distributors' body since 1876; public member directory, no count on site.
March 7-10, 2027 Palm Desert; HDA calls it its largest supply-chain event with 600+ attendees.
Federation of pharmaceutical wholesalers; biennial General Membership Meeting; member list public, no count stated.
Biopharma trade press with 3PL, wholesaler and traceability coverage; articles dated Sept 2026.
Online news community for Canadian pharmacy and medicine professionals; the distributor's customer side.
Association of Canada's pharmacy chains, banners and partners, i.e. the distributors' customers; members listed.
No independent operator forum was found; the trade is a handful of companies that talk through CAPDM and HDA.